Okogen, Inc.
Plano, United States (US) · Health and Medical
Do your work at Okogen, Inc.?
Claim this profile to manage your company.
Verified by Enterprise League
Data quality
Complete · Accuracy
Last verified
May 2026
Okogen, Inc is a US-based biotechnology company developing innovative therapeutics for ophthalmic infectious diseases, specifically focusing on acute infectious conjunctivitis.We are dedicated to addressing a significant unmet need in the treatment of pink eye, a common condition affecting millions annually.
Overview
Okogen, Inc is a US-based biotechnology company developing innovative therapeutics for ophthalmic infectious diseases, specifically focusing on acute infectious conjunctivitis.
We are dedicated to addressing a significant unmet need in the treatment of pink eye, a common condition affecting millions annually. Our lead product candidate, OKG-0303, is a ‘one-stop shop’ treatment for both bacterial and viral conjunctivitis, offering a comprehensive solution for healthcare professionals.
Okogen’s approach centers on a proprietary formulation combining antiviral, ocular decongestant, and antibacterial agents, aiming to simplify treatment and improve patient outcomes. With a growing market of $4.2 billion annually for conjunctivitis treatments, Okogen is positioned to become a leader in this space.
Currently, we are in Phase 2B clinical trials and have recently secured $3.3M in funding to advance our clinical program. Our team, led by CEO Joshua H. Moriarty and Chief Medical Officer David A. Hollander, brings extensive experience in ophthalmic pharmaceutical development.
We are dedicated to addressing a significant unmet need in the treatment of pink eye, a common condition affecting millions annually. Our lead product candidate, OKG-0303, is a ‘one-stop shop’ treatment for both bacterial and viral conjunctivitis, offering a comprehensive solution for healthcare professionals.
Okogen’s approach centers on a proprietary formulation combining antiviral, ocular decongestant, and antibacterial agents, aiming to simplify treatment and improve patient outcomes. With a growing market of $4.2 billion annually for conjunctivitis treatments, Okogen is positioned to become a leader in this space.
Currently, we are in Phase 2B clinical trials and have recently secured $3.3M in funding to advance our clinical program. Our team, led by CEO Joshua H. Moriarty and Chief Medical Officer David A. Hollander, brings extensive experience in ophthalmic pharmaceutical development.
Contact Details
info@okogen.com
Plano, United States (US)
+1
Founded
2015
Company Type
Private Limited Company
Employees
2-10
Categories
Companies teams usually look at after Okogen, Inc.
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.